Drug Profile
FT 1050
Alternative Names: 16, 16 dimethyl-prostaglandin E2; dmPGE2; FT1050; ProHema; ProHema-CB; Prostaglandin E2 - Fate TherapeuticsLatest Information Update: 02 Dec 2021
Price :
$50
*
At a glance
- Originator Childrens Hospital Boston; Massachusetts General Hospital
- Developer Fate Therapeutics
- Class Antineoplastics; Chemoprotectants; Prostaglandins; Small molecules
- Mechanism of Action Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stem cell mobilisation
Most Recent Events
- 11 Apr 2016 Fate Therapeutics terminates a phase-I trial in Stem cell mobilisation (In infants, In children, In adolescents with haematological malignancies) in USA (IV) (NCT02354417)
- 11 Apr 2016 Fate Therapeutics terminates a phase I trial for Stem cell mobilisation (in paediatric patients with metabolic disorders) in USA (NCT02354443)
- 03 Mar 2016 Discontinued - Phase-I for Stem cell mobilisation (In adolescents, In children, In infants) in USA (IV)